Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CFTR | P13569 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711137 | 1.00 | PTGER4 (0.54) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL18037660 | 0.98 | PTGER4 (0.52) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2920746 | 0.88 | PTGER4 (0.56) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2426826 | 0.85 | PTGER4 (0.54) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL1355241 | 0.85 | KDM4E (0.49) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL27862441 | 0.83 | PTGER4 (0.52) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3494181 | 0.82 | CA12 (0.47) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL9375273 | 0.81 | KDM4E (0.46) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL30969290 | 0.81 | PTGER4 (0.51) | PTGER4GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL543452 | 0.81 | ABL1 (0.53) | PTGER4GAAKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676475-A1 | HIV-1P ROTEASE INHIBITORS AND USES THEREOF | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024206093-A1 | HIV-1P ROTEASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4330250-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-117255784-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3359542-B1 | SPIRO[3H-INDOLE-3,2´-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| EP-3697758-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis Inflammasome Research, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20060103928-A1 | Projection system | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20060103769-A1 | Projection system | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20060083865-A1 | Liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20060082719-A1 | Liquid crystal display and manufacturing method of the same | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20060083868-A1 | Liquid crystal display | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-7006192-B2 | Optical element | DAI NIPPON PRINTING CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| US-20050041181-A1 | Optical element | ISHIZAKI KOJI (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6836313-B2 | Optical element | DAI NIPPON PRINTING CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| US-20030160938-A1 | Optical element | DAI NIPPON PRINTING CO., LTD. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-20030137619-A1 | Optical element | DAI NIPPON PRINTING CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387397-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | PTGER4 3538/4885GAA 1207/4885KDM4E 4506/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | PTGER4 3627/4885GAA 2736/4885KDM4E 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.